PTX Media related, page-1150

Haha.... no, my question wasn't a rhetorical one. Mind you, given how well you illustrated the confusion contained in the article, I wish you had assumed my question was rhetorical! I expected a far more subtle observation. Nevermind, so long as we are not confused.

The real reason asked is that I was hoping it would onto how our target therapy technology (aka PTX-200) appears to also be incorporated in two of our OmniCAR CarT programs... namely our trials to study solid tumours. I say this because both Her2 and EGFRviii are onogenes and not antigens that cancer cells express as such. They are the oncogenes which mutate causing the proliferation of cancer cells that express particular antigens that we can target. Well, that's my understanding. So, in other words, that's what seems to differentiate our solid turmour trials from our AML (blood cancer trial).

The AML trial is targeting the surface antigens of CD33 and CLL1... plus an intracellular antigen that MDA's TCR-like binder will hunt down and push to the surface with the aid of OmniCAR tech. The solid tumour trials looks to inhibit the AKT pathways within the cells themselves and target the antigens expressed by the oncogene mutations present in the tumours.

I only wanted to mention this because it hadn't been all that obvious to me before. As for what the various "Platform Extensions" may be, has me stumped. That was originally marked as associated with Thermo Fisher who we can't name (of course)... well, we on HC can! Dying to know more and I'm thinking that our 12-mth collab will reveal more about this in due course soon.

Anyway, so now that our overlap of Targeted Therapy (which targets genetic pathways) and CarT (which harnesses immune cells) is depicted in this picture... I can see how OmniCAR subtly incorporates the two for personalised medicine. CellPryme-A, which is also based on AKT pathway disruption, will be given as an adjuvant before, during and/or after CarT treatment. Noice!

So, our PTX100 and 200 assets are not just standalone molecular drugs. PTX200 has given rise in two different ways to OmniCAR programs and CellPryme and been interwoven into OmniCAR in a way. Interesting!